X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The proceeds will be used for the preclinical development of Trethera’s first-in-class small molecule, TRE-515, an orally delivered, therapeutic engineered to inhibit dCK, for the treatment of acute disseminated encephalomyelitis, which holds the FDA Orphan Drug designation.
Lead Product(s): TRE-515
Therapeutic Area: Immunology Product Name: TRE-515
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institute of Allergy and Infectious Diseases
Deal Size: $0.6 million Upfront Cash: Undisclosed
Deal Type: Funding August 14, 2023
Details:
The grant will fund Investigational New Drug (IND) enabling activities using TRE-515, a first-in-class deoxycytidine kinase (dCK) inhibitor, to treat systemic lupus erythematosus (SLE), a chronic autoimmune disease with significant morbidity and mortality.
Lead Product(s): TRE-515
Therapeutic Area: Immunology Product Name: TRE-515
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institute of Allergy and Infectious Diseases
Deal Size: $0.6 million Upfront Cash: Undisclosed
Deal Type: Funding June 27, 2023
Details:
The grant will fund additional patient dosing studies to identify predictive biomarkers of activity and target engagement of TRE-515, a first-in-class deoxycytidine kinase inhibitor, in solid tumors.
Lead Product(s): TRE-515
Therapeutic Area: Oncology Product Name: TRE-515
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Cancer Institute
Deal Size: $2 million Upfront Cash: Undisclosed
Deal Type: Funding May 30, 2023
Details:
TRE-515 is a potent and orally-bioavailable inhibitor of dCK that may have monotherapy activity against solid tumors where low expression of the de novo pathway or other metabolic changes occur creating greater sensitivity to nucleotide salvage pathway inhibition.
Lead Product(s): TRE-515
Therapeutic Area: Oncology Product Name: TRE-515
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 15, 2023
Details:
TRE-515 is an orally delivered first-in-class dCK inhibitor, the key enzyme in the nucleoside salvage pathway. TRE-515 is twice designated an Orphan Drug by the FDA in both optic neuritis and ADEM and is currently being studied in a Phase 1 oncology trial.
Lead Product(s): TRE-515
Therapeutic Area: Neurology Product Name: TRE-515
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2023
Details:
TRE-515 is a novel first-in-class drug, which has been shown to prevent demyelination, and even facilitate remyelination, in multiple demyelinating disease mouse models. Furthermore, the FDA has designated TRE-515 an Orphan Drug in the treatment of ON.
Lead Product(s): TRE-515
Therapeutic Area: Oncology Product Name: TRE-515
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Eye Institute
Deal Size: $1.6 million Upfront Cash: Undisclosed
Deal Type: Funding October 19, 2022
Details:
TRE-515 is an orally delivered first-in-class therapeutic selectively inhibit symptoms in experimental autoimmune encephalomyelitis (EAE) mouse models of multiple sclerosis (MS).
Lead Product(s): TRE-515
Therapeutic Area: Neurology Product Name: TRE-515
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2022
Details:
TRE-515 is a first-in-class drug targeting the enzyme deoxycytidine kinase (dCK) and currently in Phase 1 clinical trials. Trethera is currently enrolling a Phase 1 dose escalation trial to evaluate TRE-515 monotherapy in patients with various solid tumors.
Lead Product(s): TRE-515
Therapeutic Area: Neurology Product Name: TRE-515
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2022
Details:
TRE-515 is a first-in-class clinical stage drug that inhibits deoxycytidine kinase (dCK), the rate-limiting enzyme in the nucleoside salvage pathway, one of two biosynthetic pathways that generate DNA precursors.
Lead Product(s): TRE-515
Therapeutic Area: Neurology Product Name: TRE-515
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: UCLA
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2022
Details:
TRE-515, Trethera’s first-in-class drug for the treatment of acute disseminated encephalomyelitis (ADEM). ADEM is a rare autoimmune disease where patients lose their nerve function and become paralyzed, causing death in some cases.
Lead Product(s): TRE-515
Therapeutic Area: Immunology Product Name: TRE-515
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 30, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
